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Abstract
Background: A septate uterus is a uterine anomaly that may affect reproductive outcome, and is associated with
an increased risk for miscarriage, subfertility and preterm birth. Resection of the septum is subject of debate. There
is no convincing evidence concerning its effectiveness and safety. This study aims to assess whether hysteroscopic
septum resection improves reproductive outcome in women with a septate uterus.
Methods/design: A multi-centre randomised controlled trial comparing hysteroscopic septum resection and
expectant management in women with recurrent miscarriage or subfertility and diagnosed with a septate uterus.
The primary outcome is live birth, defined as the birth of a living foetus beyond 24 weeks of gestational age.
Secondary outcomes are ongoing pregnancy, clinical pregnancy, miscarriage and complications following
hysteroscopic septum resection. The analysis will be performed according to the intention to treat principle. Kaplan-
Meier curves will be constructed, estimating the cumulative probability of conception leading to live birth rate over
time. Based on retrospective studies, we anticipate an improvement of the live birth rate from 35% without surgery
to 70% with surgery. To demonstrate this difference, 68 women need to be randomised.
Discussion: Hysteroscopic septum resection is worldwide considered as a standard procedure in women with a
septate uterus. Solid evidence for this recommendation is lacking and data from randomised trials is urgently needed.
Trial registration: Dutch trial registry (NTR1676, 18th of February 2009).
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Background
A septate uterus is a congenital uterine anomaly where
the uterus is divided into two cavities. A septate uterus is
associated with reduced fertility (RR 0.86; 95% CI 0.77–
0.96), increased miscarriage rates (RR 2.9; 95% CI 2.0–4.1)
and preterm delivery (RR 2.1; 95% CI 1.5–3.1) [1].
The mechanisms behind the negative effect of the
septum on fertility and pregnancy outcome have not yet
been clarified. Suggestions are that the septum is a poor
site for embryonic implantation due to the assumed
poor vascularization, decreased sensitivity to preovula-
tory changes of the endometrium overlying the septum,
uncoordinated contractility of the septum, or a local
defect of vascular endothelial growth factor (VEGF)
receptors in the endometrium covering the septal area
[2–5]. A septate uterus is usually ascertained through re-
current pregnancy loss or subfertility, and occasionally
by other complaints such as dysmenorrhoea or preterm
birth. Approximately 6% of women with recurrent mis-
carriage and 3.5–6.4% of subfertile women, has a septate
uterus [6–8]. .In comparison, this prevalence is 2–3% in
the general female population [6, 7].
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Although evidence for the effectiveness of resecting the
uterine septum is limited, resection is considered standard
care in many countries. The evidence is mainly based
upon retrospective studies, in which improved pregnancy
chances and live birth rates after hysteroscopic septum re-
section have been suggested [9–17].
The major flaw in most of the abovementioned studies is
obviously the before/after design, since this will always
favour the tested intervention as the prognosis without the
intervention is usually good [18, 19]. At this moment, in
view of the limited quality of the performed studies it thus
remains unclear whether removal of the septum will elimin-
ate negative effects –if any- of a septate uterus, and whether
the procedure does not cause harmful side effects [20] .
To assess whether surgical intervention in women with
(recurrent) miscarriage, subfertility or preterm birth and a
septate uterus will improve reproductive outcome, we
propose The Randomised Uterine Septum Trial (TRUST).
Methods
Design
The Randomised Uterine Septum Trial (TRUST) is a mul-
ticentre randomised controlled trial in women with a sept-
ate uterus (NTR 1676). Women are randomised to
hysteroscopic septum resection or expectant management.
Recruitment has started since October 2009 and is
ongoing.
Trial population
The study population consists of women of reproductive
age with a septate uterus and a history of (recurrent) mis-
carriage, subfertility or preterm birth (Fig. 1). Women with
a contraindication to surgery are excluded for the trial.
When the study started in 2008, the study population con-
sisted of women with recurrent miscarriage and a septate
uterus. During the course of the trial we found out that it
was difficult to recruit and randomize women for the
study. Since essentially the population is women with a
septate uterus and a wish to conceive, we decided to
broaden the inclusion criteria to make an effort to identify
these women more easily. Thus in 2011 we extended the
inclusion criteria into women with a septate uterus and
recurrent miscarriage and/or subfertility, and in 2015 the
inclusion criteria were extended to women with (recur-
rent) miscarriage, subfertility or preterm birth. All amend-
ments were approved by the ethical committee of the
Academic Medical Centre (AMC), Amsterdam. Recurrent
miscarriage is defined as two or more, not necessarily con-
secutive, pregnancy losses before 20 weeks of gestational
age. Subfertility is defined as the inability to conceive for a
Fig. 1 Flowchart
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minimal period of one year of trying to conceive. The def-
inition of preterm birth is birth before a gestational age of
37 complete weeks. Only women with an active wish to
conceive are eligible for the trial. Following the most
recent ESHRE-ESGE classification, a septate uterus is
defined as all cases with an abnormal resorption of the
midline septum, a normal outline of the uterus and an in-
ternal indentation at the fundal midline exceeding 50% of
the uterine wall thickness regardless of the size of the
septum [21]. Over the years there has been a lot of discus-
sion about the classification system of uterine anomalies
and ideas about the best definition of the septate uterus
have changed [22]. After the following publication of the
ESHRE-ESGE classification, we have adjusted the defin-
ition in the study protocol accordingly to these new
insights, but it did not change our patient population
[21].The presence of a uterine septum is ascertained by
HSG, 3D ultrasound (3D-US), MRI, saline or gel infusion
sonohysterography or hysteroscopy combined with lapar-
oscopy [23–26].
Recruitment procedure
Women are recruited from outpatient clinics located in
the Netherlands, Iran and the United States of America.
Women are invited to take part in the study when a
septate uterus is diagnosed and when they meet the in-
clusion criteria.
Ethics and trial registration
Approval for this study and all subsequent amendments
have been obtained from the Medical Ethical Committee of
the Academic Medical Centre (IDS NL24082.018.08 MEC
Academic Medical Centre, Amsterdam) The Netherlands.
Local approval is obtained at all participating centres or will
be obtained before the start of recruitment. The trial is reg-
istered within the Dutch trial registry (NTR1676).
Written informed consent is obtained from women
fulfilling the inclusion criteria, prior to randomization.
Randomization
Once eligibility for the trial has been confirmed and
women have given informed consent they are rando-
mised via a web-based central randomization system to
receive either hysteroscopic septum resection or expect-
ant management .
Hysteroscopic septum resection
The intervention is hysteroscopic septum resection. The
choice for an instrument and distension medium may vary
per hospital and depends on the preference of the surgeon
and instruments available. Analgesia during surgery can be
either general anaesthesia or a loco-regional technique de-
pending on the preference of the woman and whether con-
comitant surgery, in the form of laparoscopy, is scheduled.
To prevent uterine perforation during surgery, a laparos-
copy or ultrasound has to be performed simultaneously
[27]. The choice for laparoscopy or ultrasound depends on
the local hospital protocol. To assess the results of the re-
section, a diagnostic hysteroscopy is performed 6–8 weeks
postoperatively in an outpatient setting. When a secondary
surgery is needed, this will be specified.
Expectant management
The control group will receive expectant management.
Additional interventions, such as for example aspirin or
heparin in case of co-existing antiphospholipid syndrome,
or additional artificial reproductive techniques in women
with subfertility, are allowed in both groups and will be
registered. Should the first pregnancy after randomization
result in a miscarriage, or should pregnancy not occur
after one year of follow-up, women are free to opt for add-
itional therapy, including hysteroscopic septum resection.
Outcome measures
The primary outcome measure is live birth, defined as the
birth of a living foetus beyond 24 weeks of gestational age.
Secondary outcomes are ongoing pregnancy, clinical
pregnancy, miscarriage, pregnancy outcomes as placental
abruption, uterine rupture, preterm birth and mode of
delivery (vaginal versus caesarean section), perinatal
morbidity, mortality and complications following hyster-
oscopic septum resection, such as uterine perforation,
fluid overload and endometritis.
Follow up
Follow up will take place for at least one year. Women who
will conceive in that period will be followed for the course
of that pregnancy. Woman allocated for expectant manage-
ment, have the opportunity to opt for a hysteroscopic
septum resection after one year of follow up, or when the
next pregnancy results in a miscarriage. An additional time-
line shows more detail on the timeline of study (see
Additional file 1).
Statistical analysis
All analyses will be performed according to an intention
to treat basis. The primary outcome, live birth, will be
compared between the intervention and control group.
Relative risks and 95% confidence intervals will be
calculated for the relevant outcome measures. Time to
conception, resulting in live birth will also be assessed
by means of life table analysis. To estimate the cumula-
tive probability of conception resulting in live birth rate
over time Kaplan-Meier curves will be constructed. The
risk of premature birth will be estimated stratified for
gestational age. The relative risk for obstetrical and
surgical complications will be calculated.
Rikken et al. BMC Women's Health  (2018) 18:163 Page 3 of 5
Sample size
The sample size is based on retrospective studies, an-
ticipating an improvement of the live birth rate from
35% without surgery to 70% with surgery. Using a
two-sided test, an alpha-error of 5% and a beta-error
of 20%, two groups of 31 women are needed to dem-
onstrate this difference. Anticipating lost-to-follow up
and protocol violation, an additional 10% is needed.
Thus, 68 women need to be randomised.
Discussion
Until this date, hysteroscopic septum resection of a
septate uterus is standardly being performed world-
wide in women of reproductive age and a wish to
conceive [28, 29].
The evidence for this recommendation is based on
retrospective and prospective comparative studies that
suggest that restoration of the uterine morphology
can potentially have a positive effect on live birth rate
[9–17]. Most retrospective studies used their own partici-
pants as a control group. To our knowledge, over the years
nine prospective comparative studies have been published.
The studies describe miscarriage, pregnancy or live birth
rate in women with a septate uterus who consented to hys-
teroscopic septum resection, compared with women who
chose expectant management. These studies published
contradictory findings, with some studies showing signifi-
cant higher pregnancy rate in women with a septate uterus
who were treated with surgery [12, 13, 30, 31], while other
studies found no significant difference [32–35]. Thus, equi-
poise still exists and data from randomised trials are needed
to provide definitive proof of effectiveness of a septum
resection, or the lack thereof. In view of the major improve-
ments in pregnancy rates reported by the non-comparative
retrospective studies, we require a low number of partici-
pants to exclude a difference of 35% or more. By broaden-
ing our inclusion criteria we did not need to re-calculate
the sample size since our primary population, i.e. women of
reproductive age with a septate uterus, remained the same.
Over the years, many studies have been published about
the classification of uterine anomalies and the interrater
disagreement in diagnosing the septate uterus still exists
[36, 37]. We have changed the definition of the septate
uterus according to new insights leading to the ESHRE
ESGE classification, and in retrospect all women meet these
new criteria [21].
To our knowledge the TRUST trial is the first regis-
tered multi centre randomised controlled trial designed
to assess whether hysteroscopic septum resection
improves live birth rate (NTR1676). If hysteroscopic
septum resection proves to be without effect on repro-
ductive outcome, this would imply a major change in
treatment policy and adapted guidelines.
Additional file
Additional file 1: Timeline of study. (PDF 12 kb)
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